Review anchor
Rattus norvegicus
ORGANISM · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
Rattus norvegicus
CHEMBL376
ORGANISM
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Rattus norvegicus as ChEMBL target CHEMBL376. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL376
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Rattus norvegicus matters
Rattus norvegicus is reviewed as Rattus norvegicus; the current evidence base includes 152 approved drugs, 84789 compounds, and 104649 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Rattus norvegicus
Rattus norvegicus
Review this target as Rattus norvegicus.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 152 approved drugs, 84789 compounds, and 104649 assays for this target. The dominant activity type is IC50. CHEMBL265538 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL265538 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
152 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Rattus norvegicus matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
84789
Total Compounds
104649
Total Assays
152
Approved Drugs
IC50: 5831.0, KI: 433.0, EC50: 2308.0, KD: 1085.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL265538
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL1121
|
10.8 | EC50 | Approved |
|
|
No preferred name
CHEMBL384341
|
10.8 | Kd | — |
|
|
No preferred name
CHEMBL8946
|
10.8 | Ki | Clinical |
|
|
No preferred name
CHEMBL428299
|
10.8 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ETRASIMOD
CHEMBL3358920
|
2023 |
|
|
LENIOLISIB
CHEMBL3643413
|
2023 |
|
|
MAVACAMTEN
CHEMBL4297517
|
2022 |
|
|
ERTUGLIFLOZIN
CHEMBL1770248
|
2017 |
|
|
COCAINE
CHEMBL370805
|
2017 |
|
|
PASIREOTIDE
CHEMBL3349607
|
2012 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
CAPSAICIN
CHEMBL294199
|
2009 |
|
|
ICATIBANT
CHEMBL2028850
|
2008 |
|
|
MELATONIN
CHEMBL45
|
2007 |
|
|
RIMONABANT
CHEMBL111
|
2006 |
|
|
SITAXENTAN
CHEMBL282724
|
2006 |
|
|
RAMELTEON
CHEMBL1218
|
2005 |
|
|
MYCOPHENOLIC ACID
CHEMBL866
|
2004 |
|
|
DULOXETINE
CHEMBL1175
|
2004 |
|
|
ILOPROST
CHEMBL494
|
2003 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
TADALAFIL
CHEMBL779
|
2002 |
|
|
ATOMOXETINE HYDROCHLORIDE
CHEMBL1702
|
2002 |
|
|
ATOMOXETINE
CHEMBL641
|
2002 |
|
|
DEXMETHYLPHENIDATE
CHEMBL827
|
2001 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
ATOSIBAN
CHEMBL382301
|
2000 |
|
|
LEFLUNOMIDE
CHEMBL960
|
1998 |
|
|
FENOLDOPAM MESYLATE
CHEMBL1026
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
FENOLDOPAM
CHEMBL588
|
1997 |
|
|
ANAGRELIDE
CHEMBL760
|
1997 |
|
|
EPOPROSTENOL
CHEMBL1139
|
1995 |
|
|
LOSARTAN
CHEMBL191
|
1995 |
|
|
NISOLDIPINE
CHEMBL1726
|
1995 |
|
|
ALENDRONIC ACID
CHEMBL870
|
1995 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
FLUVASTATIN SODIUM
CHEMBL2218894
|
1993 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
AMLODIPINE
CHEMBL1491
|
1992 |
|
|
PAROXETINE
CHEMBL490
|
1992 |
|
|
ONDANSETRON
CHEMBL46
|
1991 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
PRAVASTATIN SODIUM
CHEMBL690
|
1991 |
|
|
PODOFILOX
CHEMBL61
|
1990 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
TOLRESTAT
CHEMBL436
|
1989 |
|
|
PINACIDIL ANHYDROUS
CHEMBL1159
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
NICARDIPINE
CHEMBL1484
|
1988 |
|
|
PERGOLIDE MESYLATE
CHEMBL1275
|
1988 |
|
|
NIMODIPINE
CHEMBL1428
|
1988 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
Source Header